PDSB on Nasdaq

PDS Biotechnology Corp

American pharmaceutical preparations company based in Berkeley Heights. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerPDSB on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersBerkeley Heights, United States2
  • Incorporated inDE3
  • Business address303A College Road East, Princeton, Nj 085403
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493002KU8ACFTSMC9352
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 46475962

See how the biggest companies compare on our leaderboards

Versamune® products, including PDS0101 (Versamune® HPV), PDS0103, and others, alone or in combination with PDS01ADC ( formerly known as PDS0301/M9241/NHS-IL-12) , as well as Infectimune® based products and the future success of such trials;4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income5678910-$31.5M in 2025+50% since 2019
-$60.0M-$40.0M-$20.0M02019: -$21.0M-$21.0M20192020: -$14.9M-$14.9M2020−29%2021: -$21.4M-$21.4M2021+44%2022: -$41.7M-$41.7M2022+94%2023: -$43.0M-$43.0M2023+3%2024: -$36.3M-$36.3M2024−16%2025: -$31.5M-$31.5M2025−13%
Net income5678910-$34.5M in 2025+393% since 2019
-$60.0M-$40.0M-$20.0M02019: -$7.0M-$7.0M20192020: -$14.8M-$14.8M2020+112%2021: -$16.9M-$16.9M2021+14%2022: -$40.9M-$40.9M2022+141%2023: -$42.9M-$42.9M2023+5%2024: -$37.6M-$37.6M2024−12%2025: -$34.5M-$34.5M2025−8%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development expenses$19.0M$22.6M
General and administrative expenses$12.5M$13.8M
Total operating expenses$31.5M$36.3M
Loss from operations-$31.5M-$36.3M
Interest income$1.2M$2.5M
Interest expense-$5.3M-$4.7M
Interest income (expenses), net-$4.1M-$2.2M
Loss before income taxes-$35.7M-$38.5M
Benefit for income taxes$1.2M$869.2K
Net loss-$34.5M-$37.6M
Comprehensive loss-$34.5M-$37.6M
Net loss per share, basic (in dollars per share)-$0.74-$1.03
Net loss per share, diluted (in dollars per share)-$0.74-$1.03
Weighted average common shares outstanding, basic (in shares)46.4M shares36.5M shares
Weighted average common shares outstanding, diluted (in shares)46.4M shares36.5M shares

Compare PDS Biotechnology Corp with another company

Leadership

Who has led PDS Biotechnology Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Brian A. Leuthner2015–2019
  2. Frank Bedu-Addo2019–now

President

  1. Brian A. Leuthner2016–2019
  2. Frank Bedu-Addo2019–now

Chief financial officer

  1. Andrew J. Einhorn2015–2017
  2. Andrew Saik2017–2020
  3. Michael N. King2020
  4. Voorhees Seth Van2021
  5. Mathew C. Hill2021–2023
  6. Lars Boesgaard2023–now

Chief operating officer

  1. Stephan Toutain2026–now
20202025
Board members and other officers (35)

Former names

  • Edge Therapeutics, Inc.Sep 16, 2009 to Mar 18, 20193

Timeline

  1. Mar 25, 2019New chief executive Frank Bedu-Addo becomes CEO13
  2. Sep 30, 2015New chief executive Brian A. Leuthner becomes CEO14
  3. Jan 22, 2009Founded PDS Biotechnology Corp is founded2

Filings

304 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 162 major events, 66 insider forms, 5 large holders, 49 other. The latest 20:

  1. Oct 14, 2026S-3 EDGAR
  2. Oct 6, 20268-K EDGAR
  3. Sep 22, 20268-K EDGAR
  4. Sep 21, 2026SCHEDULE 13D EDGAR
  5. Sep 21, 20263 EDGAR
  6. Sep 21, 20263 EDGAR
  7. Sep 21, 20268-K EDGAR
  8. Sep 18, 20263 EDGAR
  9. Sep 14, 20268-K EDGAR
  10. Sep 8, 20268-K EDGAR
  11. Sep 4, 20268-K EDGAR
  12. Aug 25, 20268-K EDGAR
  13. Aug 19, 20268-K EDGAR
  14. Aug 14, 20268-K EDGAR
  15. Aug 13, 202610-Q EDGAR
  16. Aug 13, 20268-K EDGAR
  17. Aug 11, 20268-K EDGAR
  18. Jul 31, 20268-K EDGAR
  19. Jul 21, 2026EFFECT EDGAR
  20. Jul 21, 2026424B4 EDGAR

The 304 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 28, 2025Freitag Gregory GeneDirectorBuy15,060$1.66$25.0KForm 4
Feb 28, 2025Glover Stephen C.DirectorBuy15,061$1.66$25.0KForm 4
Dec 13, 2021HILL MATTHEW CChief Financial OfficerBuy3,100$8.99$27.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 52. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC1,699,315$1.5M0.0%+68,226
Focus Partners Wealth642,177$565.8K0.0%New
Quantinno Capital Management LP642,177$565.8K0.0%New
BlackRock, Inc.607,639$535.4K0.0%+53,591
Geode Capital Management, LLC587,139$517.4K0.0%−73,089
Vanguard Fiduciary Trust Co357,144$314.6K0.0%+49,833
Militia Capital Management LLC331,800$292.3K0.1%New
Citadel Advisors LLC323,801$285.3K0.0%New
Morgan Stanley313,922$276.6K0.0%+310,000
Blair William & Co/il300,000$264.3K0.0%No change
Jane Street Group, LLC279,664$246.4K0.0%New
Renaissance Technologies LLC252,200$222.2K0.0%+31,400
Inspirion Wealth Advisors, LLC188,995$165.2K0.0%+7,000
Marshall Wace, Llp147,171$129.5K0.0%New
State Street Corp133,333$117.5K0.0%No change
Northern Trust Corp126,502$111.5K0.0%+17,609
Wells Fargo & Company/mn109,000$96.0K0.0%−1,500
Commonwealth Equity Services, LLC92,997$81.9K0.0%+2,200
Iron Gate Global Advisors LLC70,406$62.0K0.0%−4,616
Bank of New York Mellon Corp68,491$60.3K0.0%−820
Tempus Wealth Planning, LLC61,800$54.5K0.0%No change
Two Sigma Securities, LLC41,391$36.5K0.0%+9,910
Susquehanna International Group, Llp36,328$32.0K0.0%+14,276
Raymond James Financial Inc33,819$29.8K0.0%+23,583
XTX Topco Ltd33,098$29.2K0.0%−3,113

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57